See more : BioForce Nanosciences Holdings, Inc. (BFNH) Income Statement Analysis – Financial Results
Complete financial analysis of HUTCHMED (China) Limited (HCM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of HUTCHMED (China) Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Topy Industries, Limited (7231.T) Income Statement Analysis – Financial Results
- Sebang Co., Ltd (004360.KS) Income Statement Analysis – Financial Results
- Infinite Acquisition Corp. (NFNT-WT) Income Statement Analysis – Financial Results
- Function International Public Company Limited (FTI.BK) Income Statement Analysis – Financial Results
- Intertape Polymer Group Inc. (ITPOF) Income Statement Analysis – Financial Results
HUTCHMED (China) Limited (HCM)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.hutch-med.com
About HUTCHMED (China) Limited
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 838.00M | 426.41M | 356.13M | 227.98M | 204.89M | 214.11M | 241.20M | 216.08M | 178.20M | 91.81M | 45.97M | 195.39M | 166.92M | 134.51M | 111.00M | 86.97M | 65.11M | 50.43M | 37.86M |
| Cost of Revenue | 384.45M | 311.10M | 258.23M | 188.52M | 160.15M | 143.94M | 175.82M | 156.33M | 110.78M | 72.05M | 22.21M | 99.40M | 74.16M | 54.64M | 44.59M | 36.13M | 27.66M | 21.32M | 14.62M |
| Gross Profit | 453.55M | 115.31M | 97.89M | 39.46M | 44.74M | 70.17M | 65.38M | 59.75M | 67.43M | 19.76M | 23.76M | 95.99M | 92.77M | 79.87M | 66.41M | 50.84M | 37.45M | 29.11M | 23.24M |
| Gross Profit Ratio | 54.12% | 27.04% | 27.49% | 17.31% | 21.84% | 32.77% | 27.11% | 27.65% | 37.84% | 21.53% | 51.69% | 49.13% | 55.57% | 59.38% | 59.83% | 58.46% | 57.52% | 57.72% | 61.40% |
| Research & Development | 303.06M | 267.59M | 207.45M | 111.23M | 91.94M | 78.82M | 50.68M | 66.87M | 47.37M | 33.47M | 23.44M | 5.89M | 7.29M | 6.41M | 3.86M | 8.81M | 5.64M | 2.77M | 2.05M |
| General & Administrative | 79.78M | 92.17M | 89.30M | 50.02M | 39.21M | 30.91M | 23.96M | 21.58M | 19.62M | 22.57M | 21.30M | 35.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 53.39M | 43.93M | 37.83M | 11.33M | 13.72M | 17.74M | 19.32M | 18.00M | 10.21M | 4.11M | 3.45M | 62.68M | 56.50M | 52.70M | 44.81M | 31.74M | 23.09M | 16.04M | 18.20M |
| SG&A | 133.18M | 136.11M | 127.13M | 61.35M | 52.93M | 48.65M | 43.28M | 39.58M | 29.83M | 26.68M | 24.75M | 98.41M | 56.50M | 52.70M | 44.81M | 31.74M | 23.09M | 16.04M | 18.20M |
| Other Expenses | 0.00 | 119.31M | 91.64M | 63.54M | 44.88M | -781.00K | 116.00K | 609.00K | 184.00K | 261.00K | 65.00K | -1.01M | 23.39M | -225.46K | -282.96K | -1.22M | -937.60K | -557.58K | -175.47K |
| Operating Expenses | 436.23M | 523.00M | 426.21M | 236.13M | 189.76M | 161.01M | 118.80M | 106.59M | 77.20M | 26.87M | 23.14M | 95.36M | 87.18M | 82.46M | 71.51M | 64.98M | 47.36M | 34.50M | 29.16M |
| Cost & Expenses | 819.62M | 834.10M | 684.45M | 424.64M | 349.91M | 304.95M | 294.62M | 262.92M | 187.97M | 98.92M | 45.35M | 194.76M | 161.34M | 137.10M | 116.10M | 101.11M | 75.01M | 55.82M | 43.77M |
| Interest Income | 36.15M | 9.60M | 2.08M | 3.24M | 4.94M | 5.98M | 1.22M | 502.00K | 451.00K | 559.00K | 451.00K | 578.00K | 133.65K | 225.46K | 282.96K | 1.22M | 937.60K | 559.54K | 175.47K |
| Interest Expense | 759.00K | 652.00K | 592.00K | 787.00K | 1.03M | 1.01M | 1.46M | 1.63M | 1.40M | 1.05M | 1.01M | 737.00K | 561.03K | 402.38K | 399.37K | 527.87K | 299.15K | 388.73K | 495.45K |
| Depreciation & Amortization | 8.21M | 8.66M | 7.19M | 6.06M | 4.94M | 3.59M | 2.58M | 2.30M | 2.02M | 1.27M | 963.00K | 4.05M | 4.56M | 4.58M | 4.57M | 4.65M | 3.80M | 2.87M | 2.32M |
| EBITDA | 25.53M | -401.11M | -207.96M | -182.89M | -135.13M | -82.06M | -49.50M | -43.39M | -7.16M | -17.17M | 1.58M | -6.79M | 10.20M | 2.37M | -46.89K | -9.58M | -5.92M | -2.51M | -3.42M |
| EBITDA Ratio | 3.05% | -94.07% | -92.46% | -80.22% | -65.95% | -38.32% | -20.52% | -20.08% | -4.00% | -6.36% | 3.44% | -3.48% | 6.11% | 2.01% | 0.13% | -10.88% | -8.61% | -4.83% | -9.51% |
| Operating Income | 18.38M | -409.77M | -336.46M | -188.95M | -145.02M | -92.64M | -53.42M | -46.70M | -9.77M | 8.10M | 11.56M | 12.11M | 5.39M | -2.21M | -4.61M | -14.23M | -9.72M | -5.38M | -5.73M |
| Operating Income Ratio | 2.19% | -96.10% | -94.48% | -82.88% | -70.78% | -43.27% | -22.15% | -21.61% | -5.48% | 8.82% | 25.14% | 6.20% | 3.23% | -1.64% | -4.16% | -16.36% | -14.93% | -10.67% | -15.13% |
| Total Other Income/Expenses | 39.93M | -2.73M | 112.58M | 6.93M | 5.28M | 5.99M | -119.00K | -659.00K | -767.49K | 13.48M | 28.99M | -17.37M | -1.96M | -402.38K | -399.37K | -527.87K | -299.15K | -386.77K | -502.33K |
| Income Before Tax | 58.31M | -410.42M | -215.74M | -189.73M | -141.11M | -86.66M | -53.54M | -47.36M | -10.54M | 6.58M | 10.07M | 10.90M | 4.83M | -2.61M | -5.01M | -14.76M | -10.02M | -5.77M | -6.23M |
| Income Before Tax Ratio | 6.96% | -96.25% | -60.58% | -83.23% | -68.87% | -40.47% | -22.20% | -21.92% | -5.91% | 7.17% | 21.91% | 5.58% | 2.89% | -1.94% | -4.52% | -16.97% | -15.39% | -11.44% | -16.46% |
| Income Tax Expense | 4.51M | -283.00K | 11.92M | 4.83M | 3.27M | 3.96M | 3.08M | 4.33M | 1.61M | 1.34M | 1.05M | 4.16M | 3.14M | 2.58M | 2.07M | 1.50M | 837.21K | 1.96K | 141.06K |
| Net Income | 100.78M | -410.14M | -227.66M | -194.56M | -144.38M | -74.81M | -26.74M | 11.70M | 7.99M | 5.37M | 5.92M | 3.64M | 710.22K | -6.86M | -8.75M | -17.76M | -17.19M | -9.61M | -6.78M |
| Net Income Ratio | 12.03% | -96.18% | -63.93% | -85.34% | -70.47% | -34.94% | -11.08% | 5.41% | 4.49% | 5.85% | 12.87% | 1.86% | 0.43% | -5.10% | -7.88% | -20.41% | -26.40% | -19.05% | -17.90% |
| EPS | 0.59 | -0.48 | -0.29 | -0.28 | -0.22 | -0.11 | -0.04 | 0.10 | -0.32 | 0.05 | 0.06 | 0.04 | 0.01 | -0.01 | -0.02 | -0.03 | -0.03 | -0.02 | -0.02 |
| EPS Diluted | 0.58 | -0.48 | -0.29 | -0.28 | -0.22 | -0.11 | -0.04 | 0.10 | -0.32 | 0.05 | 0.06 | 0.03 | 0.01 | -0.01 | -0.02 | -0.03 | -0.03 | -0.02 | -0.02 |
| Weighted Avg Shares Out | 169.93M | 847.14M | 792.68M | 697.93M | 665.68M | 664.26M | 617.17M | 597.15M | 546.59M | 525.63M | 520.51M | 519.19M | 517.43M | 515.28M | 512.32M | 512.29M | 512.16M | 457.13M | 366.67M |
| Weighted Avg Shares Out (Dil) | 173.84M | 847.14M | 792.68M | 697.93M | 665.68M | 664.26M | 617.17M | 599.71M | 546.59M | 528.94M | 528.78M | 526.50M | 526.54M | 515.28M | 512.32M | 512.29M | 512.16M | 457.13M | 366.67M |
HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China
HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses
HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023
Wall Street Analysts See a 107.24% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?
HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan
Beware! 3 Machine Learning Stocks Waving Massive Red Flags Right Now
HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer
HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China
HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer
Source: https://incomestatements.info
Category: Stock Reports